ARV Treatment: Special Focus Back to Main Page

This is the archive of an online discussion that took place between May 4, 1998 and May 29, 1998 hosted by the AIDS Economics web site.

Please refer to the Overview for a description of the issues, the primary readings, and the key questions. See the Participants page to view biographical information provided by participants.

Also available is the final summary of the conference, by the moderator, Steve Forsythe.

Messages:

1. Announcements and Questions by Dave Witzel, 10/Apr/1998 09:26

1. "HIV's Spread is Unchecked" (background materials available) by Dave Witzel, 27/Apr/1998 11:05

2. ARV conference traffic statistics by Dave Witzel, 08/May/1998 15:26

3. New study published in AIDS by Dave Witzel, 11/May/1998 20:44

4. Materials from the face-to-face AEN meeting by Dave Witzel, 13/May/1998 21:57

1. Re: Materials from the face-to-face AEN meeting by smisra@giasdla.vsnl.net.in, 14/May/1998 19:57

5. Report of the Workshop Series on Access to HIV treatments in developing countries by Dave Witzel, 14/May/1998 10:33

1. Re: Report of the Workshop Series on Access to HIV treatments in developing countries by smisra@giasdla.vsnl.net.in, 14/May/1998 20:04

6. ARV Conference Ending by Dave Witzel, 22/May/1998 16:33 

2. Bulletin board for participants by Dave Witzel, 10/Apr/1998 09:33

1. AIDS and Economics Forum by Paurvi Bhatt, 21/Apr/1998 14:10

1. Details of AIDS Economics Network Meeting by John Stover, 28/Apr/1998 07:26

(_ Economists, please take us beyond cost-effectiveness by Claudes Kamenga, 28/Apr/1998 16:02

(_ Re: Economists, please take us beyond cost-effectiveness by Marina Mahathir, 28/Apr/1998 19:40

1. Economics and reality by Michael Halpern, 29/Apr/1998 09:25

1. Re: Economics and reality by Marina Mahathir, 29/Apr/1998 19:43

2. Re: Why Can't it be simple? by Tito Coleman, 30/Apr/1998 11:58

2. Re: Economists, please take us beyond cost-effectiveness by Joseph Brunet-Jailly, 08/May/1998 11:43

2. Additional references to the web site by Steven Forsythe, 27/Apr/1998 07:58

3. Reactions to this conference and suggestions for improvments by Dave Witzel, 19/May/1998 09:26

1. creating national fund by Hilda Abreu, 27/May/1998 09:12 

4. Topic for another conference? by Dave Witzel, 19/May/1998 09:34

1. Potential new topics by Jose A. Izazola-Licea, 20/May/1998 11:48

1. Other potential new topics by Michael Halpern, 21/May/1998 09:49

2. New conference topics by Elliot Marseille, 21/May/1998 10:56

2. Reaction to Forum by Marina Mahathir, 22/May/1998 22:18 

1. "Ethics should push the numbers" by Mead Over, 29/May/1998 15:07 

(_ Framing ethical issues by Terry Albert, 01/Jun/1998 12:22 

3. topics for another conference by jorge adrián beloqui, 23/May/1998 05:06 

4. Topic for another conference by Anita Alban, 21/May/1998 10:31

1. Macro & Micro Cost-Effectiveness by Terry Albert, 21/May/1998 13:04

2. Modelling the AIDS-epidemic by Steffen Flessa, 22/May/1998 07:45

5. Format and Further Forums ... by Jamie Uhrig, 21/May/1998 14:31

1. Suggestions for Future Topics by Michael Sweat, 22/May/1998 08:27

6. Suggestions for Future Topics by Michael Sweat, 22/May/1998 08:27

7. Format and Further Forums ... by Jamie Uhrig, 21/May/1998 14:31

3. Welcome by Steven Forsythe, 10/Apr/1998 14:43

1. Don't be shy! by Lawrence MacDonald, 20/Apr/1998 17:35

2. Thanks, Steve by Mead Over, 21/Apr/1998 11:19

3. Summary of Week #1 by Steven Forsythe, 27/Apr/1998 16:52

4. Summary of Week #2 by Steven Forsythe, 05/May/1998 22:49

1. Re: Summary of Week #2 by smisra@giasdla.vsnl.net.in, 06/May/1998 11:18

5. Summary of Weeks 3 & 4 by Steven Forsythe, 19/May/1998 09:19

1. forsythe final questions by Manuel Luján, 19/May/1998 17:59

2. need more focus on access to treatment in developing countries by Joe Thomas, 21/May/1998 08:39

6. Draft summary of online conference by Steven Forsythe, 27/May/1998 18:07 

1. Further thoughts on the ARV discussion by Mead Over, 29/May/1998 14:27 

4. Are ARVs cost-effective in developing countries? by Steven Forsythe, 13/Apr/1998 13:59

1. Cost effective to whom? by Mead Over, 21/Apr/1998 12:20

1. Costs to whom?: ambiguity between "public" and "private." by Alan G. Johnston, 23/Apr/1998 18:10

2. How important is cost-effectiveness information? by John Stover, 23/Apr/1998 08:54

2. How to determine real numbers in cost-benefit? by Hilda Abreu, 23/Apr/1998 15:27

1. Can you give an example? by Mead Over, 23/Apr/1998 17:36

2. Untitled by Rao S. Pippalla, Ph.D., 05/May/1998 00:27

3. Again, cost-effective to whom! by Waranya Teokul, 24/Apr/1998 05:55

4. Some considerations about the composition of cost and final price of durgs in pharmaceutical market by Marco Antonio A. Vitoria, 29/Apr/1998 10:40

6. Is it feasible to provide antirretrovirals in Colombia? by JUAN CESPEDES, 18/May/1998 04:43

1. Not only the costs but the epidemiological forcasts are important! by Jose A. Izazola-Licea, 18/May/1998 14:18

(_ Need for better surveillance by John Stover, 20/May/1998 07:45

(_ Re: Need for better surveillance by Tito Coleman, 20/May/1998 09:52

7. ARV for all? by Bill McGreevey, 22/May/1998 10:10 

5. Are there reasonable alternatives to public sector funding of ARVs? by Steven Forsythe, 17/Apr/1998 11:11

1. Home care alternative by Mead Over, 21/Apr/1998 11:40

2. Sharing responsibility by Pharmaceutical Industry. by Waranya Teokul, 29/Apr/1998 01:44

1. Sharing responsibility by Marina Mahathir, 29/Apr/1998 03:26

6. Are there different equity and ethical issues for HIV/AIDS? by Steven Forsythe, 17/Apr/1998 11:18

1. Government subsidies to health care by Mead Over, 21/Apr/1998 12:44

2. not only ARV equity, but "health" equity by Dominique Kerouedan, 05/May/1998 08:03

1. Re: not only ARV equity, but "health" equity by smisra@giasdla.vsnl.net.in, 05/May/1998 11:55

7. Is equitable distribution of public funding for ARV therapy possible? by Steven Forsythe, 17/Apr/1998 11:25

8. AIDS Treatment and Health Reform by Mead Over, 21/Apr/1998 11:13

1. Reality of health care expenditures by John Stover, 21/Apr/1998 16:11

1. Health Care close to break-down by Steffen Flessa, 24/Apr/1998 04:43

(_ Affordability depends on health care budget and prevalence by Steffen Flessa, 28/Apr/1998 02:08

2. Government's responses as indicators of commitment to principles by Eugene Boostrom, 22/Apr/1998 17:43

1. Help governments resist financing ARV ? by Jorge Saavedra, 28/Apr/1998 03:42

9. What should a future ARV therapy research agenda for economists consist of? by Katherine Floyd, 23/Apr/1998 08:52

1. Why isn't the answer simple? by Stefano Bertozzi, 29/Apr/1998 04:35

1. Obstacles are what you see when you take your eyes off your goal. by David Stanton, 29/Apr/1998 09:55

(_ Focus defined too narrowly? by John Stover, 01/May/1998 13:57

2. ARV treament, AIDS and society by Dr Oswaldo JAVE CASTILLO, 12/May/1998 21:27

3. predicting the unpredictable by Steffen Flessa, 19/May/1998 01:22

10. Look for solutions in poorer, but successful societies by Ralph R. Frerichs, 23/Apr/1998 23:58

1. Affordability - what can we say from costs alone by Neil Soderlund, 24/Apr/1998 17:55

(_ Use of AZT for secondary prevention by Ralph R. Frerichs, 25/Apr/1998 12:34

11. Costs of ARV and political pressure in Latinamerica by Jorge Saavedra, 25/Apr/1998 23:00

14. Framing the Ethical Issues by Terry Albert, 08/May/1998 13:11

15. Denominator in Cost-Effectiveness Ratio of ARVs by Rao S. Pippalla, Ph.D., 11/May/1998 14:17

17. What are the costs for Vietnam to use zidovudine to prevent mother-to-child transmission of HIV? by Jamie Uhrig, 19/May/1998 04:06

1. Re: What are the costs for Vietnam to use zidovudine to prevent mother-to-child transmission of HIV? by Marina Mahathir, 19/May/1998 09:02

2. The cost-effectiveness of antiviral therapy to reduce vertical transmission by Elliot Marseille, 21/May/1998 11:07

1. Targeting is only effective if done well, and a DALY question. by Jamie Uhrig, 21/May/1998 14:18

1. Response to DALY question by Elliot Marseille, 22/May/1998 12:15 

2. The dynamic effects are known to economists as "externalities" by Mead Over, 26/May/1998 16:24 

18. Long term effects of ARVs by Rao S. Pippalla, Ph.D., 21/May/1998 08:45

AIDS Economics Home Page

ARV Treatment: Special Focus Back to Main Page